OnPART™ is a novel genomic-based IP-protected precision medicine product designed to accurately assess a patient’s risk for developing moderate-to-severe side effects associated with commonly used chemotherapy regimens combined with a quantification of the patient’s perspective for how the side effects may impact his or her life.
It has been >20 years since a transformational product was introduced in cancer supportive care.
Planned milestones & capital raises will have us commercially ready to launch within 24 months.
OnPART™ Potential US Market >$2B Annually
• SEER database estimates: includes newly diagnosed pts & those with recurrent disease that will be treated with chemotherapy
• Market opportunity assumes value capture payer model of >$2500/unit
Systems & Methods using machine-learning to predict treatment regimen-related outcomes & copyrighted instrument to measure patients’ preferences (patents pending USPTO)
Have licensed 2 US patents from National Cheng Kung University for characterizing algorithmic complexity to ensure efficient analytic architecture design and faster parallel processing
International patent applications-OUS & Taiwan >150 countries
Algorithms that determine the interactions of the genes & SNPs in the networks
Analytic architecture optimized for computational efficiency